Ascendis Pharma A/S (ASND) Downgraded by BidaskClub to “Hold”
BidaskClub downgraded shares of Ascendis Pharma A/S (NASDAQ:ASND) from a buy rating to a hold rating in a research report sent to investors on Friday.
ASND has been the topic of a number of other reports. JPMorgan Chase & Co. raised their price objective on Ascendis Pharma A/S from $79.00 to $81.00 and gave the company an overweight rating in a research note on Thursday, August 30th. Stifel Nicolaus started coverage on Ascendis Pharma A/S in a research note on Tuesday, June 26th. They set a buy rating and a $85.00 price objective on the stock. ValuEngine cut Ascendis Pharma A/S from a buy rating to a hold rating in a research note on Friday, June 1st. Wells Fargo & Co raised their price objective on Ascendis Pharma A/S from $83.00 to $88.00 and gave the company an outperform rating in a research note on Thursday, August 30th. Finally, Wedbush set a $79.00 target price on Ascendis Pharma A/S and gave the stock a buy rating in a research note on Thursday, August 30th. Three research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. Ascendis Pharma A/S currently has an average rating of Buy and a consensus price target of $77.25.
ASND traded down $3.06 during trading on Friday, reaching $65.14. The stock had a trading volume of 124,228 shares, compared to its average volume of 141,634. The stock has a market cap of $2.83 billion, a PE ratio of -15.04 and a beta of 0.67. Ascendis Pharma A/S has a one year low of $26.99 and a one year high of $76.99.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.
Recommended Story: What is a closed-end mutual fund (CEF)?
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.